AstraZeneca signs $2 bln agreement with Quell to develop cell therapies

AstraZeneca signs $2 bln agreement with Quell to develop cell therapies The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications. https://ift.tt/jLN6SH4

Comments

Popular posts from this blog

Women in India Report Higher Sleep Deprivation Than Men

Nadda reviews healthcare delivery mechanisms in Rajasthan, Maharashtra

ICMR to roll out multi-state study to expand palliative care access